Veru Shares Rally After Novo Nordisk Supplies Wegovy for Phase 2b PLATEAU Trial
Veru stock jumped sharply after the company filed a clinical supply agreement with Novo Nordisk on June 4, 2026, for the Phase 2b PLATEAU study testing enobosarm together with Wegovy (semaglutide) in older adults with obesity. The pact, signed June 2, 2026, commits Novo Nordisk to provide Wegovy at no cost for the trial and grants the Danish drugma…